Eir Ventures Co-founder Magnus Persson joins the board of Portfolio company Synklino

Synklino Strengthens Board of Directors and Initiates Finance Round

Synklino ApS, a biotech company developing a first-in-class breakthrough therapy to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the appointment of Thomas Feldthus, Lene Gerlach and Magnus Persson to its Board of Directors. The new board members will join the existing board chaired by Dr. John Haurum and comprising Mr. Mads Laustsen and Scientific co-founder, professor Mette Rosenkilde. The strengthening of the board coincides with a financing round backed by current investors.

Click here to download this Press Release as PDF